Description du projet
Améliorer le développement de médicaments neuromusculaires grâce à l’analyse cinématique des mouvements chez le poisson zèbre
Les modèles animaux de maladies sont indispensables au développement de médicaments pour les traiter. Le poisson zèbre s’est révélé être un excellent système modèle pour le criblage de médicaments. Les entreprises tirent de plus en plus parti de son génome et de son système nerveux bien connus pour rechercher des médicaments contre les troubles du système moteur et les troubles neurologiques. Cependant, les méthodes d’analyse actuellement disponibles dans le commerce s’avèrent incapables de saisir la cinématique rapide associée aux réponses sensorielles et motrices. Le projet ZebraZoom, financé par le Conseil européen de la recherche, évaluera le potentiel commercial de sa plateforme à haut débit et à haute résolution, qui permet de quantifier et de catégoriser les mouvements comportementaux des larves/juvéniles de poisson zèbre en réponse à l’administration de médicaments et à des manipulations génétiques. Le plan de commercialisation qui en résultera ciblera à la fois les laboratoires de recherche et les entreprises pharmaceutiques.
Objectif
With millions of European citizens suffering from chronic pain and neurodegenerative disease, there is an urgent need for efficient solutions for drug screening in animal models. Discovery of new drugs and functions of genes involved in these human diseases relies on efficient ways to screen effects on animal behavior and at low cost. Zebrafish emerged in the last decade as an essential model for drug discovery as it is: i) a low cost genetic model organism whose genome shares 70% homology with human’s. ii) well-suited to fast and high throughput investigation of genes and molecules. iii) an ideal platform to study genes and pathways of relevance to disease in humans. Consequently, several companies are exploiting zebrafish research to devise new drugs for motor and neurological disorders. However, the current state of the art in commercial analysis of zebrafish behavior is limited to the analysis of crude parameters. In these conditions, the fast kinematics indicative of specific types of sensory and motor defects cannot be resolved. A fine kinematic analysis efficiently performed over large population of animals is crucial to reliably quantify defects in strength, posture or speed in mutant animals with and without with drug treatment. This accuracy is critical for concluding on the effects of drugs involved in motor functions, posture or pain. During her ERC starting grant OptoLoco, Dr. Wyart has developed ZebraZoom to resolve kinematic data with the necessary degree of resolution required for interpretation of motor defects. This approach enables the quantitative measurement of defects in speed, posture, and movement strength. In the ZebraZoom PoC, we will evaluate the market potential for a high-throughput method to quantify and categorise behavioural movements of zebrafish larvae/juveniles in response to drug administration and genetic manipulations and elaborate a marketing plan and business plan targeting for pharmaceutical companies and research labs.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- social scienceseconomics and businessbusiness and managementbusiness models
- natural sciencesbiological scienceszoologyichthyology
- medical and health sciencesbasic medicineneurology
- natural sciencesbiological sciencesgeneticsgenomes
Programme(s)
Régime de financement
ERC-POC - Proof of Concept GrantInstitution d’accueil
75013 Paris
France